Browse the evidence

High unfavorable dietary components (processed meats, red meats, refined grains, high-fat patterns) are associated with increased all-cause mortality but show no significant association with cardiovascular mortality after full adjustment.

Avoiding processed meats, refined grains, and high-fat patterns is important for overall survival, even if it doesn't directly predict heart disease death in this specific population. It contributes to general longevity.

Adherence to high dietary risk patterns (high DII score, high saturated fat/sodium, low fiber/omega-3) is significantly associated with increased odds of Major Adverse Cardiovascular Events (MACE), stroke, and cardiovascular mortality in patients with angiocardiopathy.

For patients with angiocardiopathy, adopting a low-inflammatory diet (low DII score) is strongly associated with reduced risk of major cardiovascular events, stroke, and death. This involves increasing intake of fruits, vegetables, fiber, and omega-3s, while reducing saturated fats, sodium, and added sugars. While this study is observational, the strong associations suggest that dietary optimization is a key component of managing cardiovascular risk in this population.

Encapsulation technologies (nanoencapsulation, cyclodextrins) can significantly increase the bioavailability of poorly bioactive polyphenols like quercetin and resveratrol by stabilizing them and facilitating transport across the mucus layer.

If you are considering high-dose polyphenol supplements, look for formulations that use encapsulation (like nanoparticles or cyclodextrins) as these are designed to overcome the body's natural barriers to absorption. However, for general health, prioritizing whole food sources is still recommended as they provide a complex matrix of nutrients.

Treating cardiovascular, kidney, and metabolic diseases as interconnected entities sharing common pathophysiological mechanisms (CKM syndrome) is superior to treating them as separate, isolated conditions.

If you have high blood pressure, high blood sugar, and kidney issues, do not treat them in isolation. Seek a care model that addresses all three simultaneously, as they likely stem from the same underlying metabolic and inflammatory drivers. This integrated approach is the current standard of care for preventing progression to heart failure or end-stage kidney disease.

Addressing mental health issues, particularly depression and anxiety, through screening and intervention improves glycemic control in patients with Type 2 Diabetes.

If you are struggling with depression or anxiety, talk to your healthcare provider. Treating mental health issues can help you manage your diabetes better and improve your blood sugar levels. Pharmacists can help screen for these issues and refer you to appropriate resources.

The fixed-dose extended-release combination of naltrexone and bupropion (NB-ER) is the most promising pharmacotherapy for facilitating smoking cessation while preventing post-cessation weight gain in individuals with obesity.

If you smoke and have obesity, your fear of gaining weight after quitting is valid and common. Standard cessation drugs often fail to stop this weight gain. Ask your doctor about NB-ER (naltrexone/bupropion extended-release), which targets the brain pathways for both addiction and hunger, offering the best chance to quit smoking without the associated weight gain.

Increasing lean body mass (LBM) below 52.26 kg is negatively associated with the risk of osteoarthritis, suggesting a protective effect, whereas increasing LBM above this threshold provides no statistically significant additional benefit.

If you have low muscle mass, building it up to around 52 kg (for women, likely higher for men depending on height/build, but the study uses absolute kg) can significantly lower your risk of developing osteoarthritis. Once you have a substantial amount of lean mass, adding more muscle won't necessarily protect your joints further, but maintaining it is still important for overall health. Focus on resistance training to build muscle if you are currently lean.

Higher levels of moderate and moderate-vigorous physical activity are associated with accelerated thickening rates of the ganglion cell-inner plexiform layer (GCIPL) and macular thickness (MT) across the full course of diabetic retinopathy, suggesting a neuroprotective structural benefit.

Regular exercise helps preserve the physical structure of your retina. Studies show that higher activity levels are linked to better maintenance of retinal layer thickness, which is crucial for preventing vision loss in diabetes. This structural benefit works alongside the risk reduction from morning exercise timing.

Body Mass Index (BMI) partially mediates the protective effect of physical activity on diabetic retinopathy, accounting for 35.7% to 58.7% of the total benefit, indicating that weight loss is a significant but not exclusive mechanism.

Exercise protects your eyes through two main paths: helping you lose weight (which accounts for about half the benefit) and improving your metabolism directly (the other half). Even if you struggle to lose weight, staying active still provides significant protection against diabetic eye disease through improved blood sugar and reduced inflammation.

Adherence to the American Heart Association's Life's Essential 8 (LE8) score is inversely associated with the risk of developing new-onset abdominal aortic aneurysm (AAA).

To lower your risk of abdominal aortic aneurysm, focus on optimizing your overall cardiovascular health using the Life's Essential 8 framework. This means aiming for ideal levels in blood pressure, cholesterol, blood sugar, and BMI, while never smoking, staying physically active, eating a healthy diet, and getting 7-9 hours of sleep. You don't need to be perfect; even small, consistent improvements in these areas can significantly reduce your risk over time. Prioritize quitting smoking and increasing physical activity, as these had the strongest individual effects in the study.

Targeted pharmacotherapy for obesity should focus on the MC4R pathway (e.g., MC4R agonists) for patients with specific genetic defects in upstream genes like POMC, PCSK1, or LEPR.

If you have a known genetic defect affecting your hunger hormones (like POMC or MC4R deficiencies), standard diets may fail. You should ask your doctor about genetic testing. If positive, you may be eligible for targeted medications like setmelanotide (Imcivree) that specifically fix the broken pathway.

Patients who transfer hospitals for secondary MBS are significantly younger, have fewer obesity-related comorbidities (hypertension, GERD), and are more likely to undergo secondary surgery for recurrent weight gain compared to those who stay.

If you are younger and generally healthy but are experiencing weight regain after your first bariatric surgery, you are part of a common group that seeks a second opinion or a different surgeon for revisional surgery. This is often driven by dissatisfaction with the amount of weight lost rather than medical complications.

Newer GLP-1 and dual-agonist obesity medications produce significant weight loss (15-21%) and metabolic benefits, but discontinuation leads to weight regain.

Use GLP-1 medications as a long-term tool for weight management, not a short-term fix. Be prepared to continue treatment to maintain weight loss, as stopping often leads to regain.

Metabolic bariatric surgery is the most effective therapy for severe obesity, providing greater weight loss and mortality reduction than pharmacotherapy.

For severe obesity, surgery offers the highest chance of significant, sustained weight loss and resolution of comorbidities. Discuss eligibility with a bariatric specialist.

GLP-1 analogs (e.g., Semaglutide, Liraglutide) and dual agonists (Tirzepatide) produce significant weight loss (up to 21%) but are associated with high costs, lifelong administration requirements, and gastrointestinal side effects that may drive patients toward complementary therapies.

GLP-1 drugs (Semaglutide, Tirzepatide) are highly effective for weight loss (15-21%), but they are expensive, require lifelong injections, and cause GI side effects. If you experience side effects or cannot afford long-term use, you are not alone; many patients seek complementary therapies like TCM to manage weight and side effects.

In patients with advanced chronic liver disease (ACLD), achieving >10% body weight loss through therapeutic lifestyle interventions significantly reduces portal hypertension and improves survival, although this magnitude of weight loss is difficult to sustain long-term.

For ACLD patients, aiming for >10% weight loss via diet and exercise can significantly lower portal pressure and improve survival. However, this is hard to maintain; consider medical weight loss aids if lifestyle changes alone fail to sustain the loss.

Bariatric surgery is an effective and durable weight-loss intervention that reduces major adverse liver outcomes (MALO) and cardiovascular events in patients with MASH, though data in advanced cirrhosis is limited.

Bariatric surgery offers significant long-term benefits for liver and heart health in MASH patients. It should be considered for eligible patients, especially when other treatments fail, despite limited data in advanced cirrhosis.

New generation obesity medications (GLP-1/GIP agonists) achieve mean weight loss of 15–25% over 68–72 weeks, narrowing the efficacy gap between medical and surgical management of obesity.

New GLP-1/GIP medications like semaglutide (2.4mg weekly) and tirzepatide are highly effective, producing 15-25% weight loss over ~1.5 years. This efficacy is now comparable to surgery, making medication a primary, not just secondary, option for obesity treatment.

Increasing cardiorespiratory fitness (CRF) reduces morbidity and mortality regardless of changes in body weight or BMI, whereas intentional weight loss in healthy overweight/obese individuals does not improve and may increase mortality risk.

Stop focusing on weight loss as the primary health goal. Instead, aim for 150 minutes of moderate-intensity physical activity per week (like brisk walking or cycling). This level of activity significantly reduces your risk of death and heart disease, regardless of whether you lose weight. Prioritize feeling stronger and more energetic over the number on the scale.

A Body Shape Index (ABSI) is associated with incident cardiovascular disease, with the highest risk observed in individuals with high ABSI combined with high RCII.

For adults over 45, monitoring your Body Shape Index (ABSI) alongside your cholesterol and inflammation levels (RCII) provides a more accurate assessment of heart disease risk than weight alone. If you have a high ABSI and high RCII, you are in a high-risk subgroup that may benefit from intensified lifestyle interventions.

Among pharmacotherapies, Semaglutide 2.4 mg and Orlistat have the most favorable safety/tolerability profiles, while Liraglutide 3.0 mg has the least tolerability, and Tirzepatide has intermediate tolerability.

When choosing a weight loss medication, be aware that tolerability varies. Semaglutide and Orlistat tend to be better tolerated, while Liraglutide may cause more side effects. Tirzepatide, despite its high efficacy, has intermediate tolerability, meaning you might experience more side effects than with Semaglutide or Orlistat.

Tirzepatide treatment in adults with obesity or overweight results in a body composition change where approximately 75% of total weight loss is fat mass and 25% is lean mass, a proportion consistent with placebo and other weight loss modalities.

If you take tirzepatide, expect to lose about 3 pounds of fat for every 1 pound of muscle. This is the same ratio you would get from dieting alone. You do not need to worry that the medication is uniquely damaging to your muscles. To protect your strength, focus on the recommended lifestyle changes: eat 500 calories less per day and move for 150 minutes a week.

Tirzepatide treatment for obesity results in a 3:1 ratio of fat mass reduction to fat-free mass (FFM) reduction, leading to improved body composition rather than proportional lean tissue loss.

If you are using Tirzepatide for weight loss, you can expect your body composition to improve favorably. The medication targets fat stores more aggressively than lean muscle tissue, resulting in roughly three times more fat loss than muscle loss. This helps maintain your metabolic rate and physical function better than traditional caloric restriction alone, which often depletes lean mass proportionally.

Short-term GPS-enabled physical activity interventions (≤3 months) produce greater weight loss effects than longer-term interventions (≥6 months).

If you start a fitness tracking program, expect the biggest results in the first 3 months. To maintain weight loss after that, you must actively work to keep the habit, as the 'newness' of the app will wear off. Consider switching to a less intrusive tracking method or adding social accountability to sustain engagement beyond the initial quarter.